The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- NJ ACTS Regulatory Knowledge Workshop 10/25
- Genetically informed Research, Education, And Treatment (GREAT)
- Join NJ ACTS Workforce Core for a Virtual Workshop on 11/11
- Join Research Resources Workshop Wednesday (R2W2) Series on 10/16 at 4pm
- Yahoo interviewed Reynold Panettieri (RITMS) on how even distant wildfires can affect lung health.
Categories
- Community (2,004)
- Covid (974)
- CTO Events (2)
- News (2,550)
- Pilots (20)